Sarepta Therapeutics, Inc. Stock price

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-22 pm EST 5-day change 1st Jan Change
134.8 USD +1.88% Intraday chart for Sarepta Therapeutics, Inc. +7.92% +39.77%
Sales 2023 * 1.23B Sales 2024 * 2B Capitalization 12.61B
Net income 2023 * -579M Net income 2024 * 306M EV / Sales 2023 * 9.78 x
Net cash position 2023 * 554M Net cash position 2024 * 1.29B EV / Sales 2024 * 5.66 x
P/E ratio 2023 *
-21.1 x
P/E ratio 2024 *
37.2 x
Employees 1,162
Yield 2023 *
-
Yield 2024 *
-
Free-Float 95.53%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Sarepta Therapeutics, Inc.

1 day+1.88%
1 week+7.92%
Current month+13.27%
1 month+11.34%
3 months+60.89%
6 months+18.55%
Current year+39.77%
More quotes
1 week
130.50
Extreme 130.5
136.50
1 month
115.98
Extreme 115.98
143.00
Current year
91.34
Extreme 91.3439
143.00
1 year
55.25
Extreme 55.25
159.89
3 years
55.25
Extreme 55.25
159.89
5 years
55.25
Extreme 55.25
181.83
10 years
8.00
Extreme 8
181.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 17-06-25
Director of Finance/CFO 48 14-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 61 17-06-25
Chairman 71 09-03-30
Director/Board Member 65 15-06-01
More insiders
Date Price Change Volume
24-02-22 134.8 +1.88% 763,563
24-02-21 132.3 -2.83% 805,983
24-02-20 136.1 +1.14% 1,008,778
24-02-16 134.6 +7.78% 2,766,289
24-02-15 124.9 +0.47% 771,621

Delayed Quote Nasdaq, February 22, 2024 at 04:00 pm EST

More quotes
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It develops therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
134.8 USD
Average target price
158.7 USD
Spread / Average Target
+17.72%
Consensus
1st Jan change Capi.
+39.77% 12 608 M $
+4.87% 110 B $
+9.77% 104 B $
+8.68% 23 902 M $
-11.35% 22 243 M $
-25.63% 21 573 M $
-7.33% 18 925 M $
-14.61% 16 036 M $
+1.24% 13 271 M $
+0.88% 12 102 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Sarepta Therapeutics, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer